Ketamine Harm Reduction

Ketamine prescribed off label is a legal possibility for some use cases. Your medical provider and pharmacist will discuss the various indications and risks involved. Talk to your independent medical provider to see if you might be a candidate for medicine in conjunction with psychotherapy.

Ketamine Harm Reduction
Ketamine Harm Reduction
Feb 2025: Ketamine Research Foundation Releases New Ketamine Guidelines for personal ketamine use

Ketamine, and other medicines, are often associated as the stigmatizing term "club drug". The safety and efficacy of ketamine for a number of mental health and physiological indications have been studied since 1962, however ketamine is only FDA-approved as a dissociative anesthetic and sedative. The FDA approved one half of the molecule of ketamine, esketamine, for Treatment Resistant Depression with and without suicidality. This approach supports a medical patient during the acute administration of a medicine, which must be done in speciality clinics certified by a pharmaceutical corporation, who sponsored the studies, and sell the medicine. Insurance companies may cover this approach, which also requires starting a second medicine known as an antidepressant, which is a chronic daily or several-times per week treatment for people who have been diagnosed by a physician as depressed and possibly suicidal. This requires at least 2 hours of time in the clinic, often several times a week.

Notes from the Field: Ketamine Detection and Involvement in Drug Overdose Deaths — United States, July 2019–June 2023

Ketamine prescribed off -label is a possibility for some use cases, and your medical provider and pharmacist will discuss the various indications and risks involved in various doses and routes of administration.

Talk to your independent medical provider to see if you might be a candidate for this ketamine in conjunction with cognitive behavioral therapy. Your medical provider will discuss other treatment approaches and options as indicated by ongoing, rigorous study and multidisciplinary clinical consultation. You are welcome to ask your provider for a referral for a cognitive behavioral therapy who specializes in ketamine.

The psychedelic approach in cognitive behavioral therapy emphasizes Self-discovery and reliance, working with the least amount of medicine needed for the maximum personal and social benefit and least amount of harmful side effects, referring and collaborating with your ongoing medical and mental health provider/s. Ketamine, like any psychoactive medicine prescribed for home use, has safety precautions which include setting up the ideal conditions for use.

Medicines of all types have effects on the body, positive, neutral and harmful. Working with a medical provider and mental health team offers an accessible way to a cutting-edge medicine, tending to some of the risks that come with recreational or underground use.

Ketamine is a medicine to be used in conjunction with a balanced, rational medical and mental health approach. Ketamine may elicit a personal experience with the medicine that has been described in research and anecdotally as "psychedelic".

While people may come at psychedelic experiences with any sort of medicine, in any sort of location or context, ketamine in conjunction with cognitive behavioral therapy offers psycho-education to clients to prevent misuse/s of medicines which may go on to become a psychological craving in some people. There are clear cases of misuses, with deaths attributed to ketamine being occasional, yet sometimes high-profile.

Ketamine psychedelic therapy by mouth uses the minimum bio-available ketamine in a sub-anesthetic range, to maximal effect balanced between psychedelic experience and amount of medicine to elicit lasting changes in the body, in terms of pain and brain function. Cognitive behavioral therapy is a secular, evidence-based, mind-body approach to tend to what effects ketamine has on the mind and the ongoing experience of being a person in a body. For people with moderate depression, who are not in a crisis state, at-home ketamine may be an option, for others, treatment may be recommended in a psychotherapy office, psychiatry clinic, ER, or in-patient unit.

Support before, during, and after the medicine administration is essential.

If you, or someone you know is interested in ketamine harm reduction education, supervision, or support, here are some resources:

Breaking the cycle: a systematic review of neurobiological mechanisms and psychotherapeutic innovations in ketamine addiction - PubMed
This systematic review synthesizes current evidence on non-prescribed ketamine use, emphasizing its neurobiological impacts and psychotherapeutic interventions. Patterns of misuse demonstrate the complex interplay of neurobiological, socio-economic, demographic and psychological factors with adolesc …
Breaking the cycle: a systematic review of neurobiological mechanisms and psychotherapeutic innovations in ketamine addiction (Lomas, 2025)

Ketamine Hydrochloride Monograph for Professionals - Drugs.com
Ketamine Hydrochloride reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI).
Ketamine | National Institute on Drug Abuse
Learn more about the dissociative drug ketamine.
Cracking the Ketamine Code
NIMH supported science and NIMH researchers helped pave the way for the development of ketamine—a groundbreaking treatment that has improved the lives of those who are impacted by treatment-resistant depression.
Spravato Side Effects: Common, Severe, Long Term
Learn about the side effects of Spravato (esketamine), from common to rare, for consumers and healthcare professionals.
Ketalar Interactions Checker - Drugs.com
409 medications are known to interact with Ketalar. Includes gabapentin, sertraline, trazodone.

Ketamine drug interactions

On the death of Matthew Perry, the New York Times reported:

"The medical examiner’s office said that drowning, coronary artery disease and the effects of an opioid, buprenorphine, had contributed to his death. But the autopsy ascribed his death primarily to “the acute effects of ketamine.”

As noted in the above resource, 409 medications are known to interact with ketamine, including the opioid buprenorphine, noted as a possible severe interaction. Additional warnings for people with:

Mixing drugs, also known as poly-drug use, or adding alcohol on top of untreated medical conditions increase risk of misuse and dangerous outcomes.

Individual reactions to ingesting something into your body, food, water, medicine, recreational drugs, alcohol, chemotherapy, antidepressants may occur, some of which are fatal. When you plan to ingest something into your body that may effect your thoughts, feelings or behaviors, consult a medical professional and a psychotherapist for counseling, especially when having feelings of harming your Self or someone else.

Acetaminophen Toxicity - StatPearls - NCBI Bookshelf
Acetaminophen (N-acetyl-para-aminophenol, paracetamol, APAP) toxicity is common primarily because the medication is so readily available, and there is a perception that it is very safe. More than 60 million Americans consume acetaminophen on a weekly basis. Acetaminophen is used in many products in combination with other preparations, especially with opioids and diphenhydramine. Many people are not aware that it is contained in these combination medications.[1][2][3]

Acetaminophen (Tylenol) toxicity is the second most common cause of liver transplantation worldwide and the most common cause of liver transplantation in the US. It is responsible for 56,000 emergency department visits, 2,600 hospitalizations, and 500 deaths per year in the United States. Fifty percent of these are unintentional overdoses. Perspective is important. ANY medicine may be misused.

To reiterate, psychedelics in conjunction with psychotherapy is a mental health approach that has been studied and practiced in some form or another for over 100 years, and ongoing, exhaustive study on these substances, including ketamine, replicable and predictable effects on people in short term use, with studies on ketamine repeated dosing in various regimens from daily to ongoing for over 18 years. There are clinical conditions that have been flagged as needing more support with this approach, requiring a medical consultation, prescription from a licensed pharmacy, and support from mental health specialists like counselors, therapists, social workers, chaplains, death doulas, hospice care worker, etc, in settings ranging from at home in bed, to group therapy sessions in retreat settings, in emergency rooms, urgent care centers, telehealth practices, and elsewhere.

If you feel in immediate danger of hurting your Self or others, please call 988 in the US, or visit https://www.iasp.info/crisis-centres-helplines/ for local assistance.

Crisis Centres & Helplines - IASP
Whilst IASP does not offer crisis support, we share a resolve and responsibility to connect people in crisis to the help they want.

On Ketamine Bladder Risks (Mini-Review of the Literature)

Certain individuals with repeated ketamine use, especially at doses above 1 gram per day, have been reported in the literature. Consulting with your medical provider reduces the likelihood of harm to your body, and ensures ketamine remains a medicine that can help you, and not a poison that hurts you.

Spotlight: On “Rare but relevant: Ketamine-induced cystitis - an in-depth review for addiction medicine” (Abdelrhamen, et Belal 2025) and psychedelic harm reduction psychotherapy, support
Rare in ketamine use disorder. Rarer still in ketamine psychedelic assisted psychotherapy as prescribed by your medical provider with support from a mental health specialist, supportive cognitive behavioral therapy approaches to mental health, recovery and harm reduction.

Multiorgan dysfunction related to chronic ketamine abuse (Pappachan, et al, 2014)

Ketamine abuse more than three times weekly for more than 2 years has been found to be a significant risk factor for urinary tract disease (9). Although recovery is observed in most cases with an early intervention, irreversible damage may occur in chronic cases.
Cholestasis related to chronic ketamine abuse has been described recently (1011). The exact mechanism for cholestasis is not known. Biliary dyskinesia resulting from the direct effect of the drug on the smooth muscles or through the vagus nerve may be the cause of cholestasis. Full recovery from the hepatobiliary disease over time has been observed with complete abstinence from ketamine abuse (1011).
Chronic abdominal pain is a common presenting complaint in ketamine abusers. The reported prevalence of upper gastrointestinal symptoms is up to 75% (212). Gastritis has been demonstrated in 85% of those who had endoscopy (12). Complete relief of the symptoms is observed in most cases when patients abstain from the drug. Gastric dilatation and severe reflux esophagitis caused by chronic ketamine abuse has not been described in the medical literature previously. Ketamine has been shown to reduce the lower esophageal sphincter tone in nonhuman models (13). Smooth muscle relaxation in the upper gastrointestinal tract might have caused dysmotility, dilatation, and stasis of food in the stomach and chronic esophageal reflux in this patient. The severe cachexia mimicking malignant disease observed in our patient could have been related to upper gastrointestinal disease and the associated poor nutrition, although biliary dysfunction and acute kidney injury might have contributed to the pathogenesis.

Urothelial toxicity of esketamine in the treatment of depression - Psychopharmacology
Rationale Ketamine is the first widely used substance with rapid-onset antidepressant action. However, there are uncertainties regarding its potential urothelial toxicity, particularly after repeated application. In the context of rising recreational ketamine use, severe side effects affecting the human urinary tract have been reported. It is assumed that ketamine interacts with bladder urothelial cells and induces apoptosis. Objectives This study aimed to assess whether single or repeated doses of esketamine used in an antidepressant indication are associated with urinary toxicity. Methods We included male and female inpatients with a current episode of depression and a diagnosis of recurrent depressive disorder, bipolar disorder or schizoaffective disorder according to ICD-10 criteria (n = 25). The esketamine treatment schedule involved a maximum of 3× weekly dosing at 0.25–0.5 mg/kg i.v. or s.c. The primary outcome was the change in urine toxicity markers (leukocytes, erythrocytes, protein and free haemoglobin). Description of demographic, clinical and laboratory data was conducted using means, standard deviations, frequencies and percentages. Changes in urinary toxicity markers over time were evaluated using linear mixed models with gender as a covariate. Results The participants received an average of 11.4 (SD 8) esketamine treatments, and an average number of 11.2 (SD 8) urine samples were analysed over the course of treatment. Neither urinary leukocyte concentration (F(20; 3.0) = 3.1; p = 0.2) nor erythrocyte concentration (F(20;2.2) = 4.1; p = 0.2) showed a significant trend towards increase during the course of esketamine treatment. Similarly, free haemoglobin and protein concentrations, which were analysed descriptively, did not display a rise during treatment. There was a significant improvement in depression ratings after esketamine treatment (p < 0.001). Conclusions This study is, to the best of our knowledge, the first to focus on urothelial toxicity of esketamine used in antidepressant indication and dose. The results indicate that the use of single or repeated doses of esketamine is unlikely to cause urothelial toxicity. The results are in need of confirmation as sample size was small.



"The results indicate that the use of single or repeated doses of esketamine at 0.25–0.5 mg/kg is unlikely to cause urothelial toxicity."

https://www.psychiatrist.com/jcp/depression/oral-ketamine-for-depression-practical-considerations/



"There were no cases of bladder toxicity."

Urothelial toxicity of esketamine in the treatment of depression - Psychopharmacology
Rationale Ketamine is the first widely used substance with rapid-onset antidepressant action. However, there are uncertainties regarding its potential urothelial toxicity, particularly after repeated application. In the context of rising recreational ketamine use, severe side effects affecting the human urinary tract have been reported. It is assumed that ketamine interacts with bladder urothelial cells and induces apoptosis. Objectives This study aimed to assess whether single or repeated doses of esketamine used in an antidepressant indication are associated with urinary toxicity. Methods We included male and female inpatients with a current episode of depression and a diagnosis of recurrent depressive disorder, bipolar disorder or schizoaffective disorder according to ICD-10 criteria (n = 25). The esketamine treatment schedule involved a maximum of 3× weekly dosing at 0.25–0.5 mg/kg i.v. or s.c. The primary outcome was the change in urine toxicity markers (leukocytes, erythrocytes, protein and free haemoglobin). Description of demographic, clinical and laboratory data was conducted using means, standard deviations, frequencies and percentages. Changes in urinary toxicity markers over time were evaluated using linear mixed models with gender as a covariate. Results The participants received an average of 11.4 (SD 8) esketamine treatments, and an average number of 11.2 (SD 8) urine samples were analysed over the course of treatment. Neither urinary leukocyte concentration (F(20; 3.0) = 3.1; p = 0.2) nor erythrocyte concentration (F(20;2.2) = 4.1; p = 0.2) showed a significant trend towards increase during the course of esketamine treatment. Similarly, free haemoglobin and protein concentrations, which were analysed descriptively, did not display a rise during treatment. There was a significant improvement in depression ratings after esketamine treatment (p < 0.001). Conclusions This study is, to the best of our knowledge, the first to focus on urothelial toxicity of esketamine used in antidepressant indication and dose. The results indicate that the use of single or repeated doses of esketamine is unlikely to cause urothelial toxicity. The results are in need of confirmation as sample size was small.

https://www.researchgate.net/profile/Luke-Jelen/publication/349251889_Ketamine_for_depression/links/60560e33458515e8345ccc0c/Ketamine-for-depression.pdf



"It should be noted that recreational ketamine consumption tends to be several orders of magnitude higher (one survey reported 34% of users reported use of 1 g or more in a typical session(Winstock et al., 2012)) than the doses prescribed in the clinical setting for depression. Although adverse effects of long-term ketamine use on the bladder would not necessarily be expected with the therapeutic dosing and frequency used in the treatment of depression, the lack of assessment of urinary symptoms has been another limitation in RCTs of ketamine (Short et al., 2018)."

https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.1022.6283&rep=rep1&type=pdf



"Additionally, concerns have been raised about the possible incidence of bladder toxicity with repeated ketamine use (Middela, 2011). Only future clinical research can establish whether maintenance ketamine infusions represent a safe and effective option for initial ketamine responders."

https://www.tandfonline.com/doi/pdf/10.1080/00952990.2020.1769118

"Scientific data show that, in a clinical setting, the applied doses of ketamine are well-tolerated by humans and its negative effects are manageable. These effects seem to be dose and frequency-related, which is strongly supported by the scientific literature and by the analyzed threads, where the adverse effects of ketamine were mentioned as mild and manageable."

https://core.ac.uk/download/pdf/161939325.pdf

"The most serious of these side effects is ketamine-induced ulcerative cystitis or ‘ketamine bladder’. This is a recently identified condition characterised by extremely painful and frequent urination that seems to have severe and potentially long lasting impacts on the patient. However, drug users who take ketamine less than daily have not reported, and show no evidence of ‘ketamine bladder’.

Self Management and Recovery Training (SMART)

Learn About SMART Recovery - SMART Recovery
Learn about SMART Recovery with these videos and slideshows. Learn what to expect at meetings, how SMART Recovery works, and get started with the ABC and CBA tools from the SMART Recovery Toolbox. Check out the SMART Recovery ABOUT video (below). What to Expect at a SMART Recovery Meeting Lorie…

SMART Recovery was established in 1994 to meet the increasing demand of those seeking a secular and evidence-informed alternative to the widespread 12-Step addiction recovery program based on cognitive behavioral therapy. SMART Recovery also trains facilitators and mental health providers and allied fields.

SMART Recovery picks up with at home and community resources where cognitive behavioral therapy leaves off, especially for people dealing with problematic behaviors like substance dependence. Building this resource into the treatment plan offers another safeguard against the misuse of medicines, or other compulsive types of cravings and behaviors that end with personal and/or social harm. They offer great tools, regular meetings around the world and online.

Our services — SMART Recovery International

66 years ago, the founder of Alcoholics Anonymous tried LSD — and ignited a controversy still raging today
Bill Wilson, the founder of Alcoholics Anonymous, was ostracized for saying LSD could benefit alcoholics. Modern science is proving him right.
Fireweed Collective
Fight to heal, heal to fight
Home
Mission: To carry a message of recovery, empowerment, hope and healing to people with lived experience with mental health issues, trauma, and extreme states.

"Emotional crisis is a universal experience. It can happen to anyone, at any time. When we are exposed to this extraordinary situation, we develop amazing and creative ways to protect ourselves, To onlookers, these protective mechanisms may look very odd, even “crazy”. To us, they have meaning. Through using eCPR we can better understand and overcome our fear of seemingly unusual behavior brought on by an emotional crisis. Through eCPR we learn how to form supportive connections that empower the person in emotional crisis so they are able to feel revitalized and quickly resume meaningful roles in the community."

Crisis Text Line | Text HOME to 741741 Free, 24/7 Mental Health Support
Crisis Text Line is a nonprofit organization that provides free, 24/7, confidential text-based mental health support in English and Spanish. Since its launch in 2013, people in need of emotional support initiated more than 9 million conversations with Crisis Text Line in the US and over 12 million globally. We’re here for everything: anxiety, depression, self-harm, bullying. Text HOME to 741741.


National Suicide Prevention Lifeline – US: 1-800-273-TALK (8255)
http://www.suicidepreventionlifeline.org/
24-hour, toll-free, confidential suicide prevention hotline available to anyone in suicidal crisis or emotional distress. Your call is routed to the nearest crisis center in the national network of more than 150 crisis centers.

SAMHSA (Substance Abuse and Mental Health Services Administration) – US: 1-800-662-HELP (4357)
http://www.samhsa.gov/find-help
SAMHSA offers 24-hour free and confidential treatment referral and information about mental and/or substance use disorders, prevention, and recovery. They also have a Disaster Distress helpline and a Veteran’s Crisis Line.

Take a Mental Health Test
Start your mental health journey here.

About Us

Psychedelic Safety Institute

Protective Behavioral Strategies for Psychedelic Use: A Mini Review of the Evidence - PubMed
There is a need to continue developing and validating measures of psychedelic PBS and outcomes for use within research and intervention settings. Additional research examining associations between psychedelic PBS use and outcomes is also critical to best serving the needs of individuals who use psyc …
Protective Behavioral Strategies for Psychedelic Use: A Mini Review of the Evidence (Piercey, et al, 2024)

Support Center El Faro | ICEERS | Assistance with challenging experiences
ICEERS Support Center has extensive experience supporting people going through difficult processes with psychoactive plants.
Mastodon Mastodon